Xconomy National

Archives

by in
Entry Author Date Location
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles Luke Timmerman 12/23/11 Seattle
Celgene To Pump $45M into Quanticel to Discover Cancer Drugs, Gets Option To Acquire Luke Timmerman 11/04/11 San Francisco
Ambrx Grabs $24M Upfront in New Diabetes, Heart Failure Research Deal With Bristol-Myers Luke Timmerman 09/22/11 San Diego
Zymeworks Snags $187M Deal With Merck to Discover Multi-Pronged Antibodies Luke Timmerman 08/29/11 Seattle
Anaphore Snags $110M Deal With Mitsubishi Tanabe to Make Drugs for Immune Disorders Luke Timmerman 12/13/10 San Diego
Sutro Biopharma Grabs $36.5M in Venture Deal to Make “Biobetters” Luke Timmerman 11/17/10 San Francisco
Novartis-backed Genomics Institute Names Martin Seidel as New Director, Replacing Peter Schultz Luke Timmerman 10/05/10 San Diego
How Novartis Got Its Vaccines Groove Back, Intellikine Gets a Drug Development Deal, Ambrx CEO Departs, & More San Diego Life Sciences News Bruce V. Bigelow 07/15/10 San Diego
Allozyne, After a Stealthy Year on a Slim Budget, Re-Emerges with MS Drug and Fat Pipeline Luke Timmerman 07/14/10 Seattle
Peter Schultz Exits Top Job at Genomics Institute of the Novartis Research Foundation Luke Timmerman 07/14/10 San Diego
Ambrx CEO Steve Kaldor Departs Luke Timmerman 07/12/10 San Diego
The 20-Year Outlook for San Diego Life Sciences: Sold Out? Not Anymore Luke Timmerman 03/15/10 San Diego
The 20-Year Future of San Diego Biotech, Coming March 31 Luke Timmerman 03/09/10 San Diego
What Will San Diego’s Biotech Hub Look Like in 20 Years? Xconomy Event Takes Long View Luke Timmerman 02/16/10 San Diego
Biogen Idec CEO Stepping Down, Ambrx Focuses on Empowered Antibodies, Intellikine Testing First Drug Candidate, & More San Diego Life Sciences News Bruce V. Bigelow 01/07/10 San Diego
Ambrx, Saying Thanks to its Rivals, Rides Wave of Interest in “Empowered” Antibodies Luke Timmerman 01/06/10 San Diego
Swine Flu Could Benefit Some Biomedical Companies, Local Biotechs Are Looking Healthier, Arena Happy With Obesity Drug Results, & More San Diego Life Sciences News Bruce V. Bigelow 09/24/09 San Diego
Ambrx Strikes Deal With Wyeth (Soon-to-be Pfizer) to Make Antibody Drugs Luke Timmerman 09/18/09 San Diego
Intellikine, Stocked With Cash, Pushes Portfolio of Drugs Against Biology’s Hot Targets Luke Timmerman 08/18/09 San Diego
Wireless Medicine Gets $45M Booster Shot, Arena’s Weight-Loss Trial Underwhelms Wall Street, Venter’s Synthetic Genomics About to Ramp Up, & Other San Diego BizTech News Bruce V. Bigelow 04/06/09 San Diego
Ambrx Gets $10 Million in Venture Round Juha-Pekka Tikka 04/01/09 San Diego
Biogen Idec, Extending Life of its Top-Selling Drug, Eyes Longer-Lasting Shot for MS Luke Timmerman 03/27/09 Boston
Biotech CEOs Discuss the Virtues of Going Virtual Bruce V. Bigelow 03/26/09 San Diego
Pacira and Histogen Disclose Layoffs, Optimer Advances Diarrhea Drug, Torrey Path Comes to Town, & More SD BizTech Bruce V. Bigelow 03/02/09 San Diego
UW’s Gardasil Windfall, Cell Therapeutics Unloads Zevalin, Trubion Cuts Jobs, & More Seattle-Area Life Sciences News Luke Timmerman 02/26/09 Seattle
Ambrx Nails Down Partnership with Merck KGaA to Develop Multiple Sclerosis Drug Luke Timmerman 02/24/09 San Diego
Ambrx Aims to Create New Breed of Custom-Built Biotech Drugs Luke Timmerman 12/08/08 San Diego
Ambrx Garners $28,364,000 New Round VentureDeal 06/30/06 San Diego
Page 1 of 1
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.